China Approves First Golimumab Biosimilar as Bio-Thera Clinches Unprecedented US-EU-China Triple in 2026
Chinese biopharmaceutical company Bio-Thera Solutions has received marketing authorization from China's National Medical Products Administration (NMPA) for BAT2506 — now branded 阿舒立® (ASHULI) — making it the first approved biosimilar to golimumab ( …